July 17, 2025
| Today’s news and insights for biopharma leaders
UPDATED
On a conference call, CEO Doug Ingram said the decision to cut 36% of the company's staff and halt several drug programs was essential to ensuring Sarepta's "long-term viability."
|
Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said Thursday. But the details, and their potential consequences, are still not clear.
|
The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who aren’t insured or are willing to pay cash for their medications.
|
Pharma’s speed advantage depends on trust. Is your data foundation strong enough?
|
UPDATED
Sino's acquisition of LaNova Medicines is the first large buyout of a China-based drugmaker tracked by BioPharma Dive since BioNTech's deal for Biotheus last year.
|
Quarterly pharmaceutical sales surpassed $15 billion for the first time as strong performance from J&J's cancer medicines offset slumping Stelara sales.
|
|
Real-world data (RWD) is crucial for healthcare decision-making. Learn best practices for maximizing regulatory, payer, HEOR and commercial impact through strategic data management in this playbook.
|
|
From Our Library
Playbook
Custom content for DNA Genotek
|
Playbook
Custom content for Cardinal Health
|
Webinar - on demand
Custom content for PurpleLab
|
Playbook
Custom content for Inovalon
|
| 
